Yiteng Jin

Yiteng Jin

Auto-generated profile, based on publicly available information

Yiteng Jin

Center for Quantitative Biology, Academy for Advanced Interdisciplinary Studies, Peking University, Beijing, China

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 August 2025 in Journal of Experimental Medicine
Verified
Journal Article
Closed access
KTKaiyang Tang
Kaiyang Tang
LWLijian Wu
Lijian Wu
YHYuanzhi Hu
Yuanzhi Hu
TXTeng Xue
Teng Xue
YJYiteng Jin
Yiteng Jin
DPDeng Pan
Deng Pan
Effective immunotherapy relies on the presentation of tumor-derived neoantigens on the major histocompatibility complex class I (MHC-I) to activate CD8+ T cells. Deficiencies in this process are a key mechanism of immune evasion and resistance to checkpoint blockade. In this study, using an in vivo CRISPR-Cas9 screen, we unexpectedly found that inactivation of calreticulin (CALR), and other selected components of the peptide-loading complex (PLC), induced robust CD8+ T cell–mediated immune responses. We show that this effect is dependent on the expression of classical MHC-I on tumor cells. Mechanistically, loss of CALR reshaped the MHC-I peptide repertoire, favoring the presentation of low-affinity peptides in murine and human cell lines. Genetic or pharmacological inhibition of PDIA3, another PLC component, similarly induced antitumor effects. These findings reveal a previously unrecognized role of CALR and the PLC in regulating antitumor immunity and suggest that targeting this pathway could be a promising strategy to overcome immune resistance and improve the efficacy of cancer immunotherapies.

7 August 2023 in Physical Review Research
Verified
Journal Article
Open access
PDF file
LMLingyu Meng
Lingyu Meng
YJYiteng Jin
Yiteng Jin
YGYichao Guan
Yichao Guan
JXJiayi Xu
Jiayi Xu
JLJie Lin
Jie Lin
Experiments have found that diffusion in metabolically active cells is much faster than in dormant cells, especially for large particles. However, the mechanism of this size-dependent diffusion enhancement in living cells is still unclear. In this Letter, we approximate the net effect of metabolic processes as a white-noise active force and simulate a model system of bacterial cytoplasm with a highly polydisperse particle size distribution. We find that diffusion enhancement in active cells relative to dormant cells can be more substantial for large particles. Our simulations agree quantitatively with the experimental data of Escherichia coli, suggesting an autocorrelation function of the active force proportional to the cube of the particle radius. We demonstrate that such a white-noise active force is equivalent to an active force of about 0.57 pN with random orientation. Our work unveils an emergent simplicity of random processes inside living cells.

7 August 2024 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
LWLiang Wen
Liang Wen
WHWei Hu
Wei Hu
SHSen Hou
Sen Hou
CLCe Luo
Ce Luo
YJYiteng Jin
Yiteng Jin
YMYuanguang Meng
Yuanguang Meng
Background: Despite breakthroughs in treatment, ovarian cancer (OC) remains one of the most lethal gynecological malignancies, with an increasing age-standardized mortality rate. This underscores an urgent need for novel biomarkers and therapeutic targets. Although growth factor receptor-bound protein 7 (GRB7) is implicated in cell signaling and tumorigenesis, its expression pattern and clinical implications in OC remain poorly characterized. Methods: To systematically investigate GRB7’s expression in OC, our study utilized extensive datasets from TCGA, GTEx, CCLE, and GEO. The prognostic significance of GRB7 was evaluated by means of Kaplan–Meier and Cox regression analyses. Using a correlation analysis and gene set enrichment analysis, relationships between GRB7’s expression and gene networks, immune cell infiltration and immunotherapy response were investigated. In vitro experiments were conducted to confirm GRB7’s function in the biology of OC. Results: Compared to normal tissues, OC tissues exhibited a substantial upregulation of GRB7. Reduced overall survival, disease-specific survival, and disease-free interval were all connected with high GRB7 mRNA levels. The network study demonstrated that GRB7 is involved in pathways relevant to the course of OC and has a positive connection with several key driver genes. Notably, GRB7’s expression was linked to the infiltration of M2 macrophage and altered response to immunotherapy. Data from single-cell RNA sequencing data across multiple cancer types indicated GRB7’s predominant expression in malignant cells. Moreover, OC cells with GRB7 deletion showed decreased proliferation and migration, as well as increased susceptibility to T cell-mediated cytotoxicity. Conclusion: With respect to OC, our results validated GRB7 as a viable prognostic biomarker and a promising therapeutic target, providing information about its function in tumorigenesis and immune modulation. GRB7’s preferential expression in malignant cells highlights its significance in the biology of cancer and bolsters the possibility that it could be useful in enhancing the effectiveness of immunotherapy.

15 May 2026 in Nature Communications
Verified
Journal Article
Open access
SWShuo Wang
Shuo Wang
SHSen Hou
Sen Hou
CLCe Luo
Ce Luo
HZHaorui Zhang
Haorui Zhang
YJYiteng Jin
Yiteng Jin
YYYingjiang Ye
Yingjiang Ye
Microsatellite-stable/proficient mismatch repair (MSS/pMMR) colorectal cancer (CRC) is characterized by a cold tumor microenvironment, with limited CD8⁺ T cell infiltration and poor responsiveness to immune checkpoint inhibitors (ICIs). Here, using an in vivo CRISPR/Cas9 screen in a CMT93 cell-derived murine tumor model, we identify Arid3b as a key negative regulator of CD8⁺ T cell infiltration and antitumor activity. Genetic ablation of Arid3b in CD8⁺ T cells significantly enhances their intratumoral accumulation and promotes robust tumor control. Mechanistically, Arid3b deficiency upregulates Runx3 , driving a tissue-resident memory-like phenotype and effector function. Notably, the benefits conferred by Arid3b deficiency are abrogated upon Runx3 deletion, indicating a RUNX3-dependent mechanism. Together, targeting ARID3B could offer a promising strategy to reshape the tumor microenvironment and sensitize MSS CRC to immunotherapy.